Viewing Study NCT00615758

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:19 AM
Ignite Modification Date: 2026-02-28 @ 2:28 PM
Study NCT ID: NCT00615758
Status: COMPLETED
Last Update Posted: 2009-12-15
First Post: 2008-02-01
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV
Sponsor: Hellenic Oncology Research Group
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non Small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Erlotinib View
None Biological therapy View
None Tyrosin Kinase Inhibitor therapy View